APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Neprilysin Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Neprilysin Antibody Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchAnti-Neprilysin Antibody Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Neprilysin Antibody Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Anti-Neprilysin Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Neprilysin Antibody Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Neprilysin Antibody Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-Neprilysin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Neprilysin Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Neprilysin Antibody market include Bioprojet SCR, Cipla Limited, Novartis International AG, Oceanic Pharmachem Pvt. Ltd, Pharmaleads SA and Theravance Biopharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-Neprilysin Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Neprilysin Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Neprilysin Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-Neprilysin Antibody market.

Anti-Neprilysin Antibody Segment by Company

Bioprojet SCR

Cipla Limited

Novartis International AG

Oceanic Pharmachem Pvt. Ltd

Pharmaleads SA

Theravance Biopharma Inc.

Anti-Neprilysin Antibody Segment by Type

Sacubitril

TD-0714

STR-324

PL-265

LHW-090

Anti-Neprilysin Antibody Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Anti-Neprilysin Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anti-Neprilysin Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-Neprilysin Antibody key companies, revenue, market share, and recent developments.

3. To split the Anti-Neprilysin Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-Neprilysin Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Neprilysin Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Neprilysin Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neprilysin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Neprilysin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neprilysin Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Neprilysin Antibody industry.

Chapter 3: Detailed analysis of Anti-Neprilysin Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-Neprilysin Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-Neprilysin Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Neprilysin Antibody Industry Trends Table 2. Anti-Neprilysin Antibody Industry Drivers Table 3. Anti-Neprilysin Antibody Industry Opportunities and Challenges Table 4. Anti-Neprilysin Antibody Industry Restraints Table 5. Global Anti-Neprilysin Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Neprilysin Antibody Revenue Share by Company (2021-2026) Table 7. Global Anti-Neprilysin Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-Neprilysin Antibody Key Company Manufacturing Base & Headquarters Table 9. Global Anti-Neprilysin Antibody Company, Product Type & Application Table 10. Global Anti-Neprilysin Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-Neprilysin Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Sacubitril Table 15. Significant Companies of TD-0714 Table 16. Significant Companies of STR-324 Table 17. Significant Companies of PL-265 Table 18. Significant Companies of LHW-090 Table 19. Global Anti-Neprilysin Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Anti-Neprilysin Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Anti-Neprilysin Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Anti-Neprilysin Antibody Sales Value Share by Type (2021-2026) Table 23. Global Anti-Neprilysin Antibody Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Hospital Pharmacies Table 27. Global Anti-Neprilysin Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Anti-Neprilysin Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Anti-Neprilysin Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Anti-Neprilysin Antibody Sales Value Share by Application (2021-2026) Table 31. Global Anti-Neprilysin Antibody Sales Value Share by Application (2027-2032) Table 32. Global Anti-Neprilysin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Anti-Neprilysin Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Anti-Neprilysin Antibody Sales Value Share by Region (2021-2026) Table 35. Global Anti-Neprilysin Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Anti-Neprilysin Antibody Sales Value Share by Region (2027-2032) Table 37. Global Anti-Neprilysin Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-Neprilysin Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Anti-Neprilysin Antibody Sales Value Market Share by Country (2021-2026) Table 40. Global Anti-Neprilysin Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Anti-Neprilysin Antibody Sales Value Market Share by Country (2027-2032) Table 42. Bioprojet SCR Company Information Table 43. Bioprojet SCR Business Overview Table 44. Bioprojet SCR Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Bioprojet SCR Anti-Neprilysin Antibody Product Portfolio Table 46. Bioprojet SCR Recent Development Table 47. Cipla Limited Company Information Table 48. Cipla Limited Business Overview Table 49. Cipla Limited Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Cipla Limited Anti-Neprilysin Antibody Product Portfolio Table 51. Cipla Limited Recent Development Table 52. Novartis International AG Company Information Table 53. Novartis International AG Business Overview Table 54. Novartis International AG Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Novartis International AG Anti-Neprilysin Antibody Product Portfolio Table 56. Novartis International AG Recent Development Table 57. Oceanic Pharmachem Pvt. Ltd Company Information Table 58. Oceanic Pharmachem Pvt. Ltd Business Overview Table 59. Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Product Portfolio Table 61. Oceanic Pharmachem Pvt. Ltd Recent Development Table 62. Pharmaleads SA Company Information Table 63. Pharmaleads SA Business Overview Table 64. Pharmaleads SA Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pharmaleads SA Anti-Neprilysin Antibody Product Portfolio Table 66. Pharmaleads SA Recent Development Table 67. Theravance Biopharma Inc. Company Information Table 68. Theravance Biopharma Inc. Business Overview Table 69. Theravance Biopharma Inc. Anti-Neprilysin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Theravance Biopharma Inc. Anti-Neprilysin Antibody Product Portfolio Table 71. Theravance Biopharma Inc. Recent Development Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Anti-Neprilysin Antibody Product Image Figure 2. Global Anti-Neprilysin Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Neprilysin Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Neprilysin Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Sacubitril Image Figure 8. TD-0714 Image Figure 9. STR-324 Image Figure 10. PL-265 Image Figure 11. LHW-090 Image Figure 12. Global Anti-Neprilysin Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Anti-Neprilysin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Anti-Neprilysin Antibody Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Hospital Pharmacies Image Figure 18. Global Anti-Neprilysin Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Anti-Neprilysin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Anti-Neprilysin Antibody Sales Value Share by Application (2021-2032) Figure 21. Global Anti-Neprilysin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Anti-Neprilysin Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Anti-Neprilysin Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. North America Anti-Neprilysin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Anti-Neprilysin Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Anti-Neprilysin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Anti-Neprilysin Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Anti-Neprilysin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Anti-Neprilysin Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. South America Anti-Neprilysin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Anti-Neprilysin Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Anti-Neprilysin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Sacubitril
  • TD-0714
  • STR-324
  • PL-265
  • LHW-090
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Bioprojet SCR
  • Cipla Limited
  • Novartis International AG
  • Oceanic Pharmachem Pvt. Ltd
  • Pharmaleads SA
  • Theravance Biopharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Neprilysin Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Neprilysin Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-Neprilysin Antibody Market Dynamics
  1. 2.1 Anti-Neprilysin Antibody Industry Trends
  2. 2.2 Anti-Neprilysin Antibody Industry Drivers
  3. 2.3 Anti-Neprilysin Antibody Industry Opportunities and Challenges
  4. 2.4 Anti-Neprilysin Antibody Industry Restraints
3 Anti-Neprilysin Antibody Market by Company
  1. 3.1 Global Anti-Neprilysin Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Neprilysin Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Neprilysin Antibody Company Ranking (2024-2026)
  4. 3.4 Global Anti-Neprilysin Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-Neprilysin Antibody Company Product Type and Application
  6. 3.6 Global Anti-Neprilysin Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-Neprilysin Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-Neprilysin Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-Neprilysin Antibody Market by Type
  1. 4.1 Anti-Neprilysin Antibody Type Introduction
  2. 4.1.1 Sacubitril
  3. 4.1.2 TD-0714
  4. 4.1.3 STR-324
  5. 4.1.4 PL-265
  6. 4.1.5 LHW-090
  7. 4.2 Global Anti-Neprilysin Antibody Sales Value by Type
  8. 4.2.1 Global Anti-Neprilysin Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anti-Neprilysin Antibody Sales Value by Type (2021-2032)
  10. 4.2.3 Global Anti-Neprilysin Antibody Sales Value Share by Type (2021-2032)
5 Anti-Neprilysin Antibody Market by Application
  1. 5.1 Anti-Neprilysin Antibody Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Anti-Neprilysin Antibody Sales Value by Application
  6. 5.2.1 Global Anti-Neprilysin Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Neprilysin Antibody Sales Value by Application (2021-2032)
  8. 5.2.3 Global Anti-Neprilysin Antibody Sales Value Share by Application (2021-2032)
6 Anti-Neprilysin Antibody Regional Value Analysis
  1. 6.1 Global Anti-Neprilysin Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Neprilysin Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-Neprilysin Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-Neprilysin Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Neprilysin Antibody Sales Value (2021-2032)
  7. 6.3.2 North America Anti-Neprilysin Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-Neprilysin Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-Neprilysin Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-Neprilysin Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-Neprilysin Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-Neprilysin Antibody Sales Value (2021-2032)
  16. 6.6.2 South America Anti-Neprilysin Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-Neprilysin Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-Neprilysin Antibody Sales Value Share by Country, 2025 VS 2032
7 Anti-Neprilysin Antibody Country-level Value Analysis
  1. 7.1 Global Anti-Neprilysin Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Neprilysin Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-Neprilysin Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-Neprilysin Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-Neprilysin Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-Neprilysin Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-Neprilysin Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bioprojet SCR
  2. 8.1.1 Bioprojet SCR Company Information
  3. 8.1.2 Bioprojet SCR Business Overview
  4. 8.1.3 Bioprojet SCR Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bioprojet SCR Anti-Neprilysin Antibody Product Portfolio
  6. 8.1.5 Bioprojet SCR Recent Developments
  7. 8.2 Cipla Limited
  8. 8.2.1 Cipla Limited Company Information
  9. 8.2.2 Cipla Limited Business Overview
  10. 8.2.3 Cipla Limited Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Limited Anti-Neprilysin Antibody Product Portfolio
  12. 8.2.5 Cipla Limited Recent Developments
  13. 8.3 Novartis International AG
  14. 8.3.1 Novartis International AG Company Information
  15. 8.3.2 Novartis International AG Business Overview
  16. 8.3.3 Novartis International AG Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis International AG Anti-Neprilysin Antibody Product Portfolio
  18. 8.3.5 Novartis International AG Recent Developments
  19. 8.4 Oceanic Pharmachem Pvt. Ltd
  20. 8.4.1 Oceanic Pharmachem Pvt. Ltd Company Information
  21. 8.4.2 Oceanic Pharmachem Pvt. Ltd Business Overview
  22. 8.4.3 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Product Portfolio
  24. 8.4.5 Oceanic Pharmachem Pvt. Ltd Recent Developments
  25. 8.5 Pharmaleads SA
  26. 8.5.1 Pharmaleads SA Company Information
  27. 8.5.2 Pharmaleads SA Business Overview
  28. 8.5.3 Pharmaleads SA Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaleads SA Anti-Neprilysin Antibody Product Portfolio
  30. 8.5.5 Pharmaleads SA Recent Developments
  31. 8.6 Theravance Biopharma Inc.
  32. 8.6.1 Theravance Biopharma Inc. Company Information
  33. 8.6.2 Theravance Biopharma Inc. Business Overview
  34. 8.6.3 Theravance Biopharma Inc. Anti-Neprilysin Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Theravance Biopharma Inc. Anti-Neprilysin Antibody Product Portfolio
  36. 8.6.5 Theravance Biopharma Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst